Wave Life Sciences is rated Hold, reflecting high pipeline potential but significant clinical, regulatory, and commercial risks. WVE-006 regaining global rights from GSK raises both opportunity and ...
D-Wave Quantum (QBTS) was in focus on Monday as Benchmark maintained its Buy rating and $35 price target on the quantum computing company after its most recent quarterly results. Shares rose 2.9% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results